Literature DB >> 12757930

Expression of mutant and wild-type TIMP3 in primary gingival fibroblasts from Sorsby's fundus dystrophy patients.

Christine E Arris1, Debra J Bevitt, Jeseem Mohamed, Zheng Li, Kevin P Langton, Michael D Barker, Michael P Clarke, Norman McKie.   

Abstract

Gingival fibroblast cell lines were derived from Sorsby's fundus dystrophy (SFD) patients carrying the S181C TIMP3 and the E139X TIMP3 mutations. These cell lines were grown in culture to study expression of the wild-type and mutant tissue inhibitor of metalloproteinase 3 (TIMP3) alleles from a normal diploid cell type. Firstly, patient cells were found to co-express the wild-type and mutant TIMP3 alleles, S181C TIMP3 or E139X TIMP3, at the mRNA level using restriction fragment length polymorphism (RFLP) analysis. A SpeI RFLP for E139X TIMP3 is described. Low levels of endogenous TIMP3 protein expression were elevated using the natural polysaccharide calcium pentosan polysulfate (CaPPs) in combination with the cytokine IL-1alpha. Immunoblotting detected protein expression from both wild-type and mutant alleles, S181C TIMP3 or E139X TIMP3. S181C TIMP3 from these cells was found to dimerise and retain MMP2 inhibitory activity. To facilitate studies of the E139X TIMP3 protein, the allele was expressed using HighFive insect cells. In this cell type, the E139X TIMP3 was synthesised as a mixture of monomer and dimer. Both monomeric and dimeric E139X TIMP3 protein retained MMP2 inhibitory activity in gelatin zymography. Expression of mutant E139X or S181C TIMP3 protein from a normal diploid patient-derived fibroblast cell had no effect on either MMP2 or MMP9 expression or activation whilst transcribed from their normal promoter context.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12757930     DOI: 10.1016/s0925-4439(03)00036-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  A novel TIMP3 mutation associated with a retinitis pigmentosa-like phenotype.

Authors:  Meghan J DeBenedictis; Yosef Gindzin; Enrico Glaab; Bela Anand-Apte
Journal:  Ophthalmic Genet       Date:  2020-07-27       Impact factor: 1.803

2.  Oncostatin M in combination with tumour necrosis factor {alpha} induces a chondrocyte membrane associated aggrecanase that is distinct from ADAMTS aggrecanase-1 or -2.

Authors:  W Hui; H E Barksby; D A Young; T E Cawston; N McKie; A D Rowan
Journal:  Ann Rheum Dis       Date:  2005-05-05       Impact factor: 19.103

Review 3.  Sorsby fundus dystrophy: Insights from the past and looking to the future.

Authors:  Bela Anand-Apte; Jennifer R Chao; Ruchira Singh; Heidi Stöhr
Journal:  J Neurosci Res       Date:  2018-08-21       Impact factor: 4.164

4.  Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases.

Authors:  Linda Troeberg; Kazunari Fushimi; Rama Khokha; Hervé Emonard; Peter Ghosh; Hideaki Nagase
Journal:  FASEB J       Date:  2008-07-16       Impact factor: 5.191

Review 5.  The Diverse Roles of TIMP-3: Insights into Degenerative Diseases of the Senescent Retina and Brain.

Authors:  Jennifer M Dewing; Roxana O Carare; Andrew J Lotery; J Arjuna Ratnayaka
Journal:  Cells       Date:  2019-12-21       Impact factor: 6.600

Review 6.  Sorsby fundus dystrophy (SFD): A narrative review.

Authors:  Georgios Tsokolas
Journal:  Medicine (Baltimore)       Date:  2022-09-23       Impact factor: 1.817

7.  Clinical and biochemical effects of the E139K missense mutation in the TIMP3 gene, associated with Sorsby fundus dystrophy.

Authors:  Z Saihan; Z Li; J Rice; N A Rana; S Ramsden; P G Schlottmann; S A Jenkins; C Blyth; G C Black; N McKie; A R Webster
Journal:  Mol Vis       Date:  2009-06-15       Impact factor: 2.367

8.  The N-terminal p.(Ser38Cys) TIMP3 mutation underlying Sorsby fundus dystrophy is a founder mutation disrupting an intramolecular disulfide bond.

Authors:  Sarah Naessens; Julie De Zaeytijd; Delfien Syx; Roosmarijn E Vandenbroucke; Frédéric Smeets; Caroline Van Cauwenbergh; Bart P Leroy; Frank Peelman; Frauke Coppieters
Journal:  Hum Mutat       Date:  2019-02-06       Impact factor: 4.878

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.